Byondis
Tinie van Boekel is a Senior Research Scientist at Byondis since November 2013, with extensive experience in the development of immunoassays, particularly in the field of autoimmunity and rheumatoid arthritis. Prior roles include Senior Scientist positions at Sint Maartenskliniek and Wieslab BV, where responsibilities encompassed R&D project management and quality oversight. Tinie also served as Group Leader of Immunoassays at Philips, focusing on assay development using advanced biosensor technology. Tinie holds a PhD in Biology/Biochemistry from Radboud University and initially specialized in clinical chemistry. A notable research highlight includes developing a diagnostic assay for rheumatoid arthritis during a post-doctoral tenure at Radboud University, complemented by international experience at the University of California at Davis.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.